RNTX
Rein Therapeutics Inc
NASDAQ: RNTX · HEALTHCARE · BIOTECHNOLOGY
$1.36
+6.27% today
Updated 2026-04-30
Market cap
$40.66M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-1.96
Dividend yield
—
52W range
$1 – $2
Volume
0.1M
Rein Therapeutics Inc (RNTX) Financial statements
SEC filings — annual and quarterly data.
Cash flow — annual
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $-11.71M | $-15.01M | $-20.53M | $-27.93M | $-26.47M | $-20.48M | $-23.75M | $-24.86M | $-19.81M | $-22.29M | $-19.36M |
| Capital expenditures | $94000.00 | $0.00 | $142000.00 | $4.42M | $151000.00 | $5000.00 | $157000.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Depreciation | — | — | — | — | — | — | — | — | — | — | — |
| Stock-based comp | $626000.00 | $688000.00 | $1.75M | $3.28M | $2.12M | $1.89M | $2.26M | $2.08M | $1.19M | $1.12M | $2.22M |
| Free cash flow | $-11.80M | $-15.01M | $-20.67M | $-32.35M | $-26.63M | $-20.48M | $-23.91M | $-24.86M | $-19.81M | $-22.29M | $-19.36M |
| Investing cash flow | — | — | — | — | — | — | — | — | — | — | — |
| Financing cash flow | — | — | — | — | — | — | — | — | — | — | — |
| Dividends paid | — | — | — | — | — | — | — | — | — | — | — |
| Share repurchases | — | — | — | — | — | — | — | — | — | — | — |
| Debt repayment | — | — | — | — | — | — | — | — | — | — | — |
| Net change in cash | — | — | — | — | — | — | — | — | — | — | — |